I-Oramed Pharmaceuticals Inc. namhlanje ibhengeze ukuba igqibile ukubhaliswa kwesigulana kwiSigaba sesi-3 se-ORA-D-013-1 sophononongo lwe-insulin capsule yomlomo i-ORMD-0801 yonyango lwe-2 yeswekile (T2D), idlula ekujoliswe kuyo kwizigulane ezingama-675 ezine-710. abaguli ababhalisiweyo.
I-ORA-D-013-1 inkulu yezifundo ezimbini ze-Oramed zeSigaba se-3 eziqhutywa phantsi kwe-US Food and Drug Administration (FDA) evunyiweyo ye-protocols ukunyanga izigulane ze-T2D ezinolawulo olungonelanga lwe-glycemic kwixesha le-6 ukuya kwiinyanga ze-12. Idatha esebenzayo ye-ORA-D-013-1 iya kufumaneka emva kokuba zonke izigulane zigqibe inyanga yokuqala ye-6 inyanga.
“Sinochulumanco ukwazisa ukuba uphononongo lwe-insulin yomlomo lweSigaba sesi-3 sokuqala sehlabathi, oluqhutywe phantsi kweprothokholi ye-FDA, luphumeze umgama obalulekileyo ngokugqityezelwa kobhaliso. Ukulandela iinyanga ezintandathu zokugqibela zonyango, silindele ukubhengeza iziphumo eziphambili ngoJanyuwari ka-2023, utshilo umphathi we-Oramed uNadav Kidron. “Sivuya kakhulu ngethemba lokhetho lwe-insulin yomlomo kubantu abanesifo seswekile. Ukuhanjiswa ngomlomo, i-insulin yomlomo ilinganisa ukulawulwa kwe-insulin engapheliyo ngaphambi kokuba ifike egazini, ibonelela ngolawulo olungcono lwe-glucose yegazi kunye nokunciphisa imingcipheko kunye neengxaki ezinxulumene ne-insulin ene-injection, kubandakanya ukufumana ubunzima kunye ne-hypoglycemia, ngelixa kulula ukuyilawula. Ndingathanda ukubulela zonke izigulana, abaphandi kunye namaqabane abandakanyekayo kolu lingo lwezonyango, zonke zinenjongo enye yokuzisa impumelelo kunyango lwesifo seswekile. "